Investor Opportunity
Tap into an unique investment opportunity with a molecular testing company that is poised to revolutionize contamination screening in the biopharmaceutical industry.
Biopharma unsatisfied with existing solutions
MARKET TRACTION
Major biopharma companies have confirmed the importance of fast and early detection of contamination and have voiced their dissatisfaction with the lack of solutions on the market.
They’ve performed feasibility studies of the MiQLab® and are in talks with leaders of other large biopharma companies to explore more opportunities.
Investment Highlights
OPPORTUNITY
Become an early stage investor in a new and differentiated solution targeting a high-risk area of the biopharma manufacturing process
GROWTH
Unmet needs in biopharma contamination testing prime the $20 billion market for substantial growth
DEMAND
Our solution will bring fast and secure medications needed for people, our pets, and animal food production
WE’RE ON A MISSION to fully automate rapid molecular testing at the point-of-need to improve efficiencies in the biopharma, building on 40 million in existing Research & Development.
Problem
Lack Of Timely Testing Can Cost Companies Millions
Biopharmaceutical manufacturers have to continually test their biopharma reactor line process for contaminants as the Food and Drug Administration prevents the distribution of products with detectable microbial contaminants. In some instances, these tests can take 14-28 days, resulting in the detection of contaminants late in the manufacturing process which can cost companies millions of dollars in wasted products.
Solution
Our Automated Tests Are 300X Faster1
MiQLab® System is a rapid, fully automated contaminant and pathogen detection system for biopharma manufacturing. Our revolutionary testing system can detect most pathogens and biological contaminants in as little as 2 hours, helping companies detect contaminants early.
1. The first generation MiQLab system’s processing time, as compared to current traditional testing protocols, has been validated by the Company as well as by two biopharmaceutical manufacturers and several veterinary diagnostic testing veterinary service providers.